Federal - HR 5353

Eliminating Opioid Related Infectious Diseases

Introduced

March 20, 2018

Description

The bill amends the Public Health Service Act to reauthorize surveillance and education regarding infections associated with injection drug use by the CDC for $40 million per year, from 2019 - 2023. It specifically names viral hepatitis and HIV.

Our Position

Support

Commentary

AIDS United strongly supports additional funding to the CDC for strategies to address opioid use-related infectious diseases.

Original Sponsor 1

Co-Sponsors 14

Latest Actions See More/Less

  • June 13, 2018 — Received in the Senate and referred to the Senate Health, Education, Labor and Pensions Committee. Congressional Record p. S3904, S3905

  • June 12, 2018 — Measure, as amended, passed in the House by voice vote, under suspension of the rules (two-thirds vote required). Congressional Record p. H5060

  • June 12, 2018 — Walden, R-Ore., motion to suspend the rules and pass the bill, as amended, agreed to by voice vote. Congressional Record p. H5059-H5060

  • June 8, 2018 — Additional cosponsor(s): 1

    Davis, R. (R-Ill.)
  • June 5, 2018 — Additional cosponsor(s): 1

    King, P. (R-N.Y.)
  • May 24, 2018 — Additional cosponsor(s): 1

    Herrera Beutler, (R-Wash.)
  • May 23, 2018 — Additional cosponsor(s): 1

    Walden, (R-Ore.)
  • May 10, 2018 — Additional cosponsor(s): 1

    Blackburn, M. (R-Tenn.)
  • May 9, 2018 — Full committee consideration and markup held by the House Energy and Commerce Committee.

    May 9, 2018 — Committee Vote: Opioid-Related Infectious Diseases — Vote to Report

    Authorize $40 million annually in fiscal 2019 through 2023 for the secretary of Health and Human Services, acting through the Centers for Disease Control and Prevention, to make grants to public and nonprofit private entities to provide for programs to implement or maintain a surveillance system to determine the incidence of infections commonly associated with illicit drug use, including infections commonly associated with injection drug use such as viral hepatitis, HIV and infective endocarditis.

    Authorize $40 million annually in fiscal 2019 through 2023 for the secretary of Health and Human Services, acting through the Centers for Disease Control and Prevention, to make grants to public and nonprofit private entities to provide for programs to implement or maintain a surveillance system to determine the incidence of infections commonly associated with illicit drug use, including infections commonly associated with injection drug use such as viral hepatitis, HIV and infective endocarditis.

    Ordered reported favorably to the full House by voice vote.
  • April 26, 2018 — Additional cosponsor(s): 1

    Lujan Grisham, M. (D-N.M.)
  • April 25, 2018 — Subcommittee consideration and markup held by the House Energy and Commerce Committee, Subcommittee on Health.

    April 25, 2018 — Subcommittee Vote: Opioid-Related Infectious Diseases — Substitute Amendment
    Lance, R-N.J. —

    Substitute amendment that would add language to allow the secretary of Health and Human Services to make grants to public and nonprofit private entities to provide for programs to implement or maintain a surveillance system to determine the incidence of infections commonly associated with illicit drug use, including infections commonly associated with injection drug use such as viral hepatitis, HIV and infective endocarditis.

    Substitute amendment that would add language to allow the secretary of Health and Human Services to make grants to public and nonprofit private entities to provide for programs to implement or maintain a surveillance system to determine the incidence of infections commonly associated with illicit drug use, including infections commonly associated with injection drug use such as viral hepatitis, HIV and infective endocarditis.

    Adopted by voice vote.

    April 25, 2018 — Subcommittee Vote: Opioid-Related Infectious Diseases — Vote to Approve

    Authorize $40 million annually in fiscal 2019 through 2023 for the secretary of Health and Human Services, acting through the Centers for Disease Control and Prevention to make grants to public and nonprofit private entities to provide for programs to implement or maintain a surveillance system to determine the incidence of infections commonly associated with illicit drug use, including infections commonly associated with injection drug use such as viral hepatitis, HIV and infective endocarditis.

    Authorize $40 million annually in fiscal 2019 through 2023 for the secretary of Health and Human Services, acting through the Centers for Disease Control and Prevention to make grants to public and nonprofit private entities to provide for programs to implement or maintain a surveillance system to determine the incidence of infections commonly associated with illicit drug use, including infections commonly associated with injection drug use such as viral hepatitis, HIV and infective endocarditis.

    Approved for full committee consideration (as amended) by voice vote.
  • April 24, 2018 — Additional cosponsor(s): 1

    Pocan, (D-Wis.)
  • April 18, 2018 — Additional cosponsor(s): 1

    Clarke, Y. (D-N.Y.)
  • April 12, 2018 — Additional cosponsor(s): 1

    Grijalva, (D-Ariz.)
  • March 20, 2018 — Original cosponsor(s): 5

    Barton, (R-Texas)Eshoo, (D-Calif.)Matsui, (D-Calif.)
    Collins, C. (R-N.Y.)Kennedy, Joseph P. (D-Mass.)
  • March 20, 2018 — Read twice and referred to: House Energy and Commerce.Congressional Record p. H1728